Search Result

Results for "

Alpha-Synuclein Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (52) Amyloid-β (6) Apoptosis (12) Autophagy (12) Bcl-2 Family (5) Beclin1 (1) Caspase (1) DNA/RNA Synthesis (2) Drug Metabolite (1) DYRK (2) Fluorescent Dye (1) GLP Receptor (5) Insulin Receptor (5) Isotope-Labeled Compounds (2) Mitosis (3) Monoamine Oxidase (3) Necroptosis (1) NF-κB (1) OGA (1) p38 MAPK (5) Parasite (2) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (5) RIP kinase (1) Sirtuin (1) Tau Protein (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (60)

By Targets:

α-synuclein (52)

Amyloid-β (6)

Apoptosis (12)

Autophagy (12)

Bcl-2 Family (5)

Beclin1 (1)

Caspase (1)

DNA/RNA Synthesis (2)

Drug Metabolite (1)

DYRK (2)

Fluorescent Dye (1)

GLP Receptor (5)

Insulin Receptor (5)

Isotope-Labeled Compounds (2)

Mitosis (3)

Monoamine Oxidase (3)

Necroptosis (1)

NF-κB (1)

OGA (1)

p38 MAPK (5)

Parasite (2)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (5)

RIP kinase (1)

Sirtuin (1)

Tau Protein (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (10)

Metabolic Disease (7)

Neurological Disease (60)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: α-synuclein 5 alpha Reductase Serpin IFNAR PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125287

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of *alpha-synuclein* (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease .

HY-163145

*α-Synuclein* inhibitor 11**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

HY-149509

*α-Synuclein* inhibitor 9**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-152552

*α-Synuclein* inhibitor 8**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

HY-147644

*α-Synuclein* inhibitor 3**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

HY-N10306

Sycosterol A	α-synuclein	Neurological Disease
Sycosterol A is a sterol-based **α-synuclein (α-syn)** inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

HY-163519

*α-Synuclein* inhibitor 13**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

HY-156435

tau Protein/α-synuclein-IN-1	α-synuclein	Neurological Disease
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and *α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein*-IN-1 can be used in study Alzheimer’s disease .

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for *α-synuclein* aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-157806

*α-Synuclein* inhibitor 12**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of *α-Syn* (α-synuclein) aggregation and can be used in the study of neurological diseases .

HY-157308

*α-Synuclein* inhibitor 10**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-159945

tau Protein/α-synuclein-IN-2	α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and *α-syn* inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces *α-syn* oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-147668

*α-Synuclein* inhibitor 6**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

HY-147666

*α-Synuclein* inhibitor 4**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

HY-147669

*α-Synuclein* inhibitor 7**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

HY-147667

*α-Synuclein* inhibitor 5**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

HY-N0901A

Corynoxine B 3 Publications Verification	α-synuclein	Neurological Disease Cancer
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-130398

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-145580A

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

HY-157225

Brazilin-7-acetate	α-synuclein	Metabolic Disease
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .

HY-135902

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the *α-synuclein* mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-135902A

Synucleozid hydrochloride NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-N0901AR

Corynoxine B (Standard)	α-synuclein Reference Standards	Neurological Disease Cancer
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

HY-169831

HUP-55	α-synuclein	Neurological Disease
HUP-55 is a prolyl endopeptidase inhibitor (IC₅₀ = 5 nM). HUP-55 reduces the dimerization of *α-synuclein* in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of *α-synuclein* in the striatum caused by overexpression of *α-synuclein* .

HY-120475

PBT434 1 Publications Verification ATH434	α-synuclein	Neurological Disease
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .

HY-173049

2N4R Tau/α-Syn against-1	α-synuclein	Neurological Disease
2N4R Tau/α-Syn against-1 (Compound 4d) targets *α-synuclein* and tau protein, inhibits the fibrillation and oligomer formation of α-synuclein and tau proteins, exhibits disaggregation activity on Aβ fibers. 2N4R Tau/α-Syn against-1 can be used in research of Parkinson's disease and Alzheimer's disease .

HY-120475A

PBT434 mesylate 1 Publications Verification ATH434 mesylate	α-synuclein	Neurological Disease
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of *α-synuclein* aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-170553

ZPD-2	α-synuclein	Neurological Disease
ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-163739

LETC	α-synuclein	Neurological Disease
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC₅₀ of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .

HY-N0413

Hupehenine	α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-G0017

N-Desmethyl imatinib 1 Publications Verification Norimatinib; Imatinib metabolite N-Desmethyl imatinib	Drug Metabolite	Cancer
N-Desmethyl imatinib (Norimatinib) is a c-Abl tyrosine kinase inhibitor. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways, and inhibits c-Abl-related neurodegenerative activity and neuroinflammation in vitro. N-Desmethyl imatinib can be used to study neurodegenerative diseases (such as Parkinson's disease) .

HY-16009

Buntanetap (+)-Phenserine; ANVS401	α-synuclein	Neurological Disease Inflammation/Immunology
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-N1501

Beta-asarone 3 Publications Verification	α-synuclein	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-156586

Egalognastat ASN90	OGA Tau Protein	Neurological Disease
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC₅₀ value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .

HY-107811

Harmol 1 Publications Verification	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis	Neurological Disease Cancer
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-107811A

Harmol hydrochloride	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis	Neurological Disease Cancer
Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol hydrochloride can induce cell mitosis, Autophagy and Apoptosis. Harmol hydrochloride promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol hydrochloride has anti-tumor, anti-depressant and anti-aging activities. Harmol hydrochloride improves motor impairment in a mouse Parkinson's disease model .

HY-N0413R

Hupehenine (Standard)	Reference Standards α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-N0743

Senkyunolide A 2 Publications Verification	α-synuclein	Neurological Disease Inflammation/Immunology Cancer
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and *α-synuclein* phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis .

HY-16009B

Buntanetap L-Tartrate (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate	Amyloid-β	Neurological Disease
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC₅₀ = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-134050

Apostatin-1 Apt-1	RIP kinase Autophagy Apoptosis Beclin1 Necroptosis	Inflammation/Immunology
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (K_D=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin .

HY-N1501R

Beta-asarone (Standard)	α-synuclein Reference Standards	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Beta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

Cat. No.	Product Name	Type

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Dyes

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-114118F

Semaglutide, FITC labeled

Fluorescent Dyes/Probes

Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-D0914A

Fast green FCF free acid

Dyes

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Target	Research Area

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-114118

Semaglutide Maximum Cited Publications 14 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 14 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 14 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118F

Semaglutide, FITC labeled	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0901A

Corynoxine B 3 Publications Verification	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Classification of Application Fields Source classification Rubiaceae Plants Disease Research Fields Indole Alkaloids Cancer	α-synuclein
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-122958

Peucedanocoumarin III	Structural Classification Carpesium cernuum L. Source classification Coumarins Phenylpropanoids Umbelliferae Plants	α-synuclein
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-N0413

Hupehenine	Alkaloids Structural Classification Liliaceae Classification of Application Fields Fritillaria hupehensis Hsiao et K. C. Hsia Source classification Plants Inflammation/Immunology Disease Research Fields Indole Alkaloids	α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite
Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-N1501

Beta-asarone 3 Publications Verification	Acorus tatarinowii Schott Structural Classification Simple Phenylpropanols Araceae Source classification Phenylpropanoids Plants	α-synuclein
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-107811

Harmol 1 Publications Verification	Neurological Disease Classification of Application Fields Peganum harmala Linn. Source classification Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Alkaloids Monophenols Zygophyllaceae Phenols Disease Research Fields	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-N0743

Senkyunolide A 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields Cancer	α-synuclein
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and *α-synuclein* phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis .

HY-N10306

Sycosterol A	Structural Classification Animals Source classification Steroids	α-synuclein
Sycosterol A is a sterol-based **α-synuclein (α-syn)** inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

HY-130398

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-N0901AR

Corynoxine B (Standard)	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Source classification Rubiaceae Plants Indole Alkaloids	α-synuclein Reference Standards
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

HY-N0413R

Hupehenine (Standard)	Alkaloids Structural Classification Liliaceae Fritillaria hupehensis Hsiao et K. C. Hsia Source classification Plants Indole Alkaloids	Reference Standards α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite
Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-N1501R

Beta-asarone (Standard)	Acorus tatarinowii Schott Structural Classification Simple Phenylpropanols Araceae Source classification Phenylpropanoids Plants	α-synuclein Reference Standards
Beta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-107811R

Harmol (Standard)	Alkaloids Monophenols Zygophyllaceae Peganum harmala Linn. Source classification Phenols Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids	Apoptosis Monoamine Oxidase Autophagy α-synuclein Mitosis Reference Standards
Harmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-Y0790

Cuminaldehyde p-Isopropylbenzaldehyde	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite Disease Research Fields Cancer	α-synuclein
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-W010041

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as *α-synuclein* and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N2099

Onjisaponin B	Triterpenes Structural Classification Neurological Disease Classification of Application Fields Terpenoids Source classification Polygalaceae Plants Polygala tenuifolia Willd. Disease Research Fields	Autophagy Amyloid-β Caspase NF-κB Apoptosis
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-Y0790R

Cuminaldehyde (Standard) p-Isopropylbenzaldehyde (Standard)	Structural Classification Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite	α-synuclein Reference Standards
Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks